

Stephan Schilling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2506396/publications.pdf>

Version: 2024-02-01

34
papers

2,052
citations

430754

18
h-index

477173

29
g-index

34
all docs

34
docs citations

34
times ranked

1834
citing authors

#	ARTICLE	IF	CITATIONS
1	Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid- β . <i>Nature</i> , 2012, 485, 651-655.	13.7	369
2	Glutaminy cyclase inhibition attenuates pyroglutamate $A\beta$ and Alzheimer's disease-like pathology. <i>Nature Medicine</i> , 2008, 14, 1106-1111.	15.2	316
3	On the Seeding and Oligomerization of pGlu-Amyloid Peptides (in vitro). <i>Biochemistry</i> , 2006, 45, 12393-12399.	1.2	238
4	Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides. <i>Biochemistry</i> , 2009, 48, 7072-7078.	1.2	171
5	Glutaminy cyclases unfold glutamyl cyclase activity under mild acid conditions. <i>FEBS Letters</i> , 2004, 563, 191-196.	1.3	155
6	Pyroglutamate-3 Amyloid- β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease-Like Transgenic Mouse Models. <i>American Journal of Pathology</i> , 2013, 183, 369-381.	1.9	102
7	Glutaminy Cyclase in Human Cortex: Correlation with (pGlu)-Amyloid- β Load and Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 385-400.	1.2	90
8	N-terminal pyroglutamate formation of $A\beta$ ²³⁸ and $A\beta$ ²⁴⁰ enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. <i>Journal of Neurochemistry</i> , 2012, 121, 774-784.	2.1	76
9	Passive Immunization against Pyroglutamate-3 Amyloid- β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study. <i>Neurodegenerative Diseases</i> , 2012, 10, 265-270.	0.8	63
10	Substrate Specificity of Glutaminy Cyclases from Plants and Animals. <i>Biological Chemistry</i> , 2003, 384, 1583-92.	1.2	59
11	Heterologous Expression and Characterization of Human Glutaminy Cyclase: Evidence for a Disulfide Bond with Importance for Catalytic Activity. <i>Biochemistry</i> , 2002, 41, 10849-10857.	1.2	58
12	Glutaminy Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease Studies on Relation to Effective Target Occupancy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 119-130.	1.3	50
13	An anti-pyroglutamate-3 $A\beta$ vaccine reduces plaques and improves cognition in APP ^{swe} /PS1 ^{E9} mice. <i>Neurobiology of Aging</i> , 2015, 36, 3187-3199.	1.5	45
14	Passive $A\beta$ Immunotherapy: Current Achievements and Future Perspectives. <i>Molecules</i> , 2018, 23, 1068.	1.7	41
15	Glutaminy Cyclases Display Significant Catalytic Proficiency for Glutamyl Substrates. <i>Biochemistry</i> , 2009, 48, 11831-11833.	1.2	38
16	IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminy cyclase isoenzymes. <i>Biological Chemistry</i> , 2016, 397, 45-55.	1.2	23
17	Isolation and Characterization of Glutaminy Cyclases from <i>Drosophila</i> : Evidence for Enzyme Forms with Different Subcellular Localization. <i>Biochemistry</i> , 2007, 46, 10921-10930.	1.2	22
18	Focused ultrasound with anti-pGlu3 $A\beta$ enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells. <i>Journal of Controlled Release</i> , 2021, 336, 443-456.	4.8	21

#	ARTICLE	IF	CITATIONS
19	First insight into structure-activity relationships of selective meprin \hat{I}^2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2428-2431.	1.0	20
20	Development of the clinical candidate PBD-C06, a humanized pGlu3-A \hat{I}^2 -specific antibody against Alzheimer's disease with reduced complement activation. <i>Scientific Reports</i> , 2020, 10, 3294.	1.6	17
21	Phosphate ions and glutaminyl cyclases catalyze the cyclization of glutaminyl residues by facilitating synchronized proton transfers. <i>Bioorganic Chemistry</i> , 2015, 60, 98-101.	2.0	13
22	A glutaminyl cyclase-catalyzed \hat{I}^2 -synuclein modification identified in human synucleinopathies. <i>Acta Neuropathologica</i> , 2021, 142, 399-421.	3.9	13
23	Natural Products from Plants and Algae for Treatment of Alzheimer's Disease: A Review. <i>Biomolecules</i> , 2022, 12, 694.	1.8	12
24	Hydrazides Are Potent Transition-State Analogues for Glutaminyl Cyclase Implicated in the Pathogenesis of Alzheimer's Disease. <i>Biochemistry</i> , 2020, 59, 2585-2591.	1.2	11
25	Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain A \hat{I}^2 Pathology in Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11791.	1.8	10
26	Continuous assays for meprin alpha and beta using prolyl tripeptidyl aminopeptidase (PtP) from <i>Porphyromonas gingivalis</i> . <i>Analytical Biochemistry</i> , 2018, 559, 11-16.	1.1	7
27	Structure and Dynamics of Meprin \hat{I}^2 in Complex with a Hydroxamate-Based Inhibitor. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5651.	1.8	7
28	Continuous assays of glutaminyl cyclase: from development to application. <i>Spectroscopy</i> , 2004, 18, 363-373.	0.8	4
29	Evidence for Enhanced Efficacy of Passive Immunotherapy against Beta-Amyloid in CD33-Negative 5xFAD Mice. <i>Biomolecules</i> , 2022, 12, 399.	1.8	1
30	P1-077: EVIDENCE FOR INVOLVEMENT OF MEPRIN B IN FORMATION OF N-TRUNCATED AND PYROGLUTAMATE-MODIFIED (PGLU) ABETA. , 2014, 10, P331-P331.		0
31	P4-298: Meprin \hat{I}^2 is Associated with Formation of Pyroglutamate-Modified A \hat{I}^2 Peptides. <i>Alzheimer's and Dementia</i> , 2016, 12, P1147.	0.4	0
32	[P4-457]: N-TRUNCATED AND PYROGLUTAMATE-MODIFIED A \hat{I}^2 ACCELERATES AGGREGATION OF \hat{I}^2 -SYNUCLEIN <i>IN VITRO</i>. <i>Alzheimer's and Dementia</i> , 2017, 13, P1505.	0.4	0
33	P1-099: COMBINATION OF A GLUTAMINYLYL CYCLASE INHIBITOR (PQ912) AND A PYROGLUTAMATE-A \hat{I}^2 SPECIFIC ANTIBODY (PBD-C06) SHOWS ADDITIVE EFFECTS IN A MOUSE MODEL WITH ALZHEIMER'S DISEASE-LIKE PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P309.	0.4	0
34	P2-056: TARGETING ISOASPARTATE-MODIFIED A \hat{I}^2 : A DIFFERENTIAL APPROACH OF PASSIVE IMMUNOTHERAPY. <i>Alzheimer's and Dementia</i> , 2018, 14, P687.	0.4	0